---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-107152"
form_type: "8-K"
ticker: "CTMX"
cik: "0001501989"
company_name: "CytomX Therapeutics, Inc."
filed_at: "2026-03-16T23:59:59+00:00"
generated_at: "2026-05-15T11:37:00.284125+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CytomX reports 2025 revenue $76.2M, down 45% YoY; cash $137.1M; Astellas collaboration ends

## Summary
- Revenue $76.2M (down from $138.1M in 2024) on completion of BMS collaboration and lower collaboration milestones.
- Cash and investments $137.1M at Dec 31, 2025, up from $100.6M; cash runway to Q2 2027.
- Astellas terminated preclinical alliance effective Q2 2026; research with BMS, Amgen, Regeneron, Moderna continues.
- Varseta-M Phase 1 data positive; FDA alignment for potential registrational trial in late-line CRC targeted mid-2026.
- CX-801 Phase 1 combo with KEYTRUDA in melanoma initial proof-of-concept data expected by end of 2026.

## SEC filing metadata
- accession: 0001193125-26-107152
- form_type: 8-K
- ticker: CTMX
- cik: 0001501989
- company_name: CytomX Therapeutics, Inc.
- filed_at: 2026-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501989/000119312526107152/0001193125-26-107152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501989/000119312526107152/ctmx-20260316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-107152
- JSON: https://secwatch.observer/filing/0001193125-26-107152.json
- Plain text: https://secwatch.observer/filing/0001193125-26-107152.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.